Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

Clinical Data

Repotrectinib is being studied in an ongoing first-in-human dose-escalation phase 1/2 trial in patients with advanced cancers with ALK-, ROS1-, or NTRK1–3-gene fusion [1]. Thus far, 65 patients have been enrolled and have received ≥1 dose of repotrectinib in 1 of 5 dose schedules (40–240 mg once a day or 160 mg twice a day). NSCLC is the most common tumour type among the enrolled patients. In addition, 35% of patients had baseline CNS metastatic disease, of which 52% was untreated.

In this trial, most adverse events were grade 1/2 [1]. Dose-limiting toxicities were observed in two patients with NSCLC and the maximum tolerated dose has not been reached. Eight partial responses were observed; patients with responses included those who were tyrosine kinase inhibitor-naïve and who had pretreated disease, as well as in patients with solvent-front substitutions and wild-type fusions.


  1. Drilon A, Ou SI, Cho BC et al. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discov 2018; 8: 1227-1236.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings